- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05057338
Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study (CoreDISTp)
Innovative Follow-up Across Health Care Levels to Optimize Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study addresses core elements in the health services for individuals with MS, constituting approximately 11000 in Norway. The two-armed pilot feasibility-RCT will be performed across the MS-outpatient (MS-OP) clinic, Nordland Hospital Trust, Bodø (NLSH), and in two surrounding municipalities, including 30 employed participants who will be followed for 10-weeks. The new intervention and pathway, CoreDISTparticipation, builds on GroupCoreDIST, which is previously found effective short and long term compared to standard care. CoreDISTparticipation consists of three phases: a) at the MS-OP clinic, in addition to the regular consultations, the patient will have a structured digital conversation with the MS-nurse addressing work related issues and a session with a physiotherapist exploring possibilities for change in balance and walking; b) in the municipality, a physiotherapist will continue exploration of improvements, followed by four weeks of GroupCoreDIST for 60 minutes, 2 times per week supplemented with home exercise programs focusing on balance, walking and physical activity. The participants will have access to exercise programs on videos through an open website at Nord University to digitally support home training.
To promote participation in employment, a structured digital meeting between each patient, the MS-nurse, the patient's employer, and the physiotherapist (who leads the group trainings) will take place in phase b; followed by phase c) which include four weeks of outdoor group based exercises and physical activity led by a physiotherapist, for 60 minutes, 2 times per week supplemented with the same home exercise programs as in phase b.
Evaluation of employment and physical activity will be conducted using an evaluation form.
The control group will receive usual consultations at the MS-OP clinic, as well as a session with a physiotherapist at the MS-OP clinic, exploring possibilities for change in balance and walking. In the municipality the control group will follow standard care (their usual follow-up).
The research team will examine feasibility, preliminary between-group differences regarding balance, walking, physical activity level, health related quality of life and barriers in employment, as well as the users' experiences with participation in the CoreDISTparticipation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bodø, Norway
- Physiotherapy department, Nordlandssykehuset HF
-
Bodø, Norway
- Bodø Municipality
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with MS (Mc Donald's criteria), Expanded Disability Status Scale ≤3.5 (no disability-fully ambulatory with moderate disability), ≥18 years, being employed. By these criteria the study will include individuals most accessible for the intervention and who have the best prospects to maintain/improve balance, walking, physical activity and participation in employment.
Exclusion Criteria:
- Retired, pregnancy at enrolment, exacerbation within two weeks prior to enrolment and other serious conditions compromising balance, walking or work capacity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CoreDISTparticipation
a) at the MS-OP clinic, in addition to the regular consultations, the patient will have a structured digital conversation with the MS-nurse addressing work related issues and a session with a physiotherapist exploring possibilities for change in balance and walking; b) in the municipality, a physiotherapist will continue exploration of improvements, followed by four weeks of GroupCoreDIST focusing on balance, walking and physical activity and conducted in groups of 3-5 individuals with MS and led by a physiotherapist. To promote participation in employment, a structured digital meeting between each patient, the MS-nurse, the patient's employer, and the physiotherapist will take place; followed by c) four weeks of outdoor group based exercises and physical activity led by a physiotherapist, complemented with an evaluation form regarding employment and physical activity. |
CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
|
|
Active Comparator: Standard care
The control group will receive the usual consultations at the MS-OP clinic including exploration of possibilities for change in balance and walking together with physiotherapist at the MS-OP clinic.
The control group will furthermore follow standard care (their usual follow-up) in the municipality.
|
The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist.
Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity.
These will be registered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MS Work Difficulties Questionnaire-23
Time Frame: Baseline
|
How frequently individuals with MS perceive psychological/cognitive (11 items)-, physical (8 items)- and external barriers (4 items) related to their current or most recent job, and is scored by a five point scale (best score 0).
(Recently translated to Norwegian).
|
Baseline
|
|
Six-Minutes Walk Test
Time Frame: Baseline
|
Walking distance within six minutes
|
Baseline
|
|
MS Work Difficulties Questionnaire-23
Time Frame: 5 weeks post-test
|
How frequently individuals with MS perceive psychological/cognitive (11 items)-, physical (8 items)- and external barriers (4 items) related to their current or most recent job, and is scored by a five point scale (best score 0).
(Recently translated to Norwegian).
|
5 weeks post-test
|
|
Six-Minutes Walk Test
Time Frame: 5 weeks post-test
|
Walking distance within six minutes
|
5 weeks post-test
|
|
MS Work Difficulties Questionnaire-23
Time Frame: 10 week post-test
|
How frequently individuals with MS perceive psychological/cognitive (11 items)-, physical (8 items)- and external barriers (4 items) related to their current or most recent job, and is scored by a five point scale (best score 0).
(Recently translated to Norwegian).
|
10 week post-test
|
|
Six-Minutes Walk Test
Time Frame: 10 week post-test
|
Walking distance within six minutes
|
10 week post-test
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trunk Impairment Scale Norwegian Version
Time Frame: Baseline
|
Dynamic sitting balance, 6 items, top score 16.
|
Baseline
|
|
Mini Balance Evaluation Systems Test
Time Frame: Baseline
|
Pro-and reactive balance, dual task and involving sit to stand, standing and walking, 14 items on a 3 point with a top score of 28
|
Baseline
|
|
Force Platform
Time Frame: Baseline
|
The force platform measures control in standing: symmetry/asymmetry of weight bearing with eyes open/closed, postural sway of center of pressure, and weight transfer which all together will present an outcome for standing balance.
|
Baseline
|
|
Activity monitors outcome 1
Time Frame: Baseline
|
The monitors measure Physical activity levels (inactive, light, moderate, vigorous) within 7 days
|
Baseline
|
|
Activity monitors outcome 2
Time Frame: Baseline
|
The monitors measure number of steps within 7 days
|
Baseline
|
|
European Quality of Life 5-Dimension-3 Level
Time Frame: Baseline
|
Self-perceived health related quality of life regarding five domains, each with three items, and a Visual Analog Scale (0-100) recording perceived health.
|
Baseline
|
|
Multiple Sclerosis Walking Scale-12
Time Frame: Baseline
|
Limitations in walking due to MS on 12 items with a scale 1-5, best score 12
|
Baseline
|
|
Multiple Sclerosis Impact Scale-29
Time Frame: baseline
|
Self-perceived physical (13 items) and psychological (9 items) impact due to MS on health related quality of life recorded by a five point scale (best score 29)
|
baseline
|
|
Weight
Time Frame: baseline
|
Self reported weight by kilogram
|
baseline
|
|
Height
Time Frame: baseline
|
Self reported height by centimetre
|
baseline
|
|
age
Time Frame: baseline
|
Self reported age by years
|
baseline
|
|
Social status
Time Frame: baseline
|
Self reported social status; married, cohabitant, living alone
|
baseline
|
|
Type of multiple sclerosis
Time Frame: baseline
|
Self reported main types: relapsing remitting, primary progressive, secondary progressive
|
baseline
|
|
Year of diagnosis multiple sclerosis
Time Frame: baseline
|
Self reported by year
|
baseline
|
|
Medications
Time Frame: baseline
|
Self reported by type of medications
|
baseline
|
|
Expanded disability status scale
Time Frame: baseline
|
Self reported or from journal functional status at last yearly control by a neurologist
|
baseline
|
|
Occupation
Time Frame: baseline
|
Self reported
|
baseline
|
|
Percentage of work
Time Frame: baseline
|
Self reported percentage of work the previous month
|
baseline
|
|
Length of education
Time Frame: baseline
|
Self reported choices: elementary school; high school; bachelor; masters degree; Doctor of philosophy degree
|
baseline
|
|
Trunk Impairment Scale Norwegian Version
Time Frame: 5 weeks post-test
|
Dynamic sitting balance, 6 items, top score 16.
|
5 weeks post-test
|
|
Mini Balance Evaluation Systems Test
Time Frame: 5 weeks post-test
|
Pro-and reactive balance, dual task and involving sit to stand, standing and walking, 14 items on a 3 point with a top score of 28
|
5 weeks post-test
|
|
Force Platform
Time Frame: 5 weeks post-test
|
The force platform measures control in standing: symmetry/asymmetry of weight bearing with eyes open/closed, postural sway of center of pressure, and weight transfer which all together will present an outcome for standing balance.
|
5 weeks post-test
|
|
Activity monitors outcome 1
Time Frame: 5 weeks post-test
|
The monitors measure Physical activity levels (inactive, light, moderate, vigorous) within 7 days
|
5 weeks post-test
|
|
Activity monitors outcome 2
Time Frame: 5 weeks post-test
|
The monitors measure number of steps within 7 days
|
5 weeks post-test
|
|
European Quality of Life 5-Dimension-3 Level
Time Frame: 5 weeks post-test
|
Self-perceived health related quality of life regarding
|
5 weeks post-test
|
|
Multiple Sclerosis Walking Scale-12
Time Frame: 5 weeks post-test
|
Limitations in walking due to MS on 12 items with a scale 1-5, best score 12
|
5 weeks post-test
|
|
Multiple Sclerosis Impact Scale-29
Time Frame: 5 weeks post-test
|
Self-perceived physical (13 items) and psychological (9 items) impact due to MS on health related quality of life recorded by a five point scale (best score 29)
|
5 weeks post-test
|
|
Percentage of work
Time Frame: 5 weeks post-test
|
Self reported percentage of work
|
5 weeks post-test
|
|
Trunk Impairment Scale Norwegian Version
Time Frame: 10 weeks post-test
|
Dynamic sitting balance, 6 items, top score 16.
|
10 weeks post-test
|
|
Mini Balance Evaluation Systems Test
Time Frame: 10 weeks post-test
|
Pro-and reactive balance, dual task and involving sit to stand, standing and walking, 14 items on a 3 point with a top score of 28
|
10 weeks post-test
|
|
Force Platform
Time Frame: 10 weeks post-test
|
The force platform measures control in standing: symmetry/asymmetry of weight bearing with eyes open/closed, postural sway of center of pressure, and weight transfer which all together will present an outcome for standing balance.
|
10 weeks post-test
|
|
Activity monitors outcome 1
Time Frame: 10 weeks post-test
|
The monitors measure Physical activity levels (inactive, light, moderate, vigorous) within 7 days
|
10 weeks post-test
|
|
Activity monitors outcome 2
Time Frame: 10 weeks post-test
|
The monitors measure number of steps within 7 days
|
10 weeks post-test
|
|
European Quality of Life 5-Dimension-3 Level
Time Frame: 10 weeks post-test
|
Self-perceived health related quality of life regarding
|
10 weeks post-test
|
|
Multiple Sclerosis Walking Scale-12
Time Frame: 10 weeks post-test
|
Limitations in walking due to MS on 12 items with a scale 1-5, best score 12
|
10 weeks post-test
|
|
Multiple Sclerosis Impact Scale-29
Time Frame: 10 weeks post-test
|
Self-perceived physical (13 items) and psychological (9 items) impact due to MS on health related quality of life recorded by a five point scale (best score 29)
|
10 weeks post-test
|
|
Percentage of work
Time Frame: 10 weeks post-test
|
Self reported percentage of work
|
10 weeks post-test
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Petter Oien, PhD, Nordlandssykehuset HF
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CoreDISTparticipation
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on CoreDISTparticipation
-
Nordlandssykehuset HFUniversity Hospital of North Norway; The Royal Norwegian Ministry of Health; Norwegian... and other collaboratorsActive, not recruitingMultiple SclerosisNorway